FrancophonIA/ELRC3.0 huggingface dataset:
English: The renal adenoma/carcinoma, the urinary bladder and urethra papilloma, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumours of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day, representing approximately 1.7 or 1 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 1.2 times the daily exposure in children and adolescents (based on AUC) at 340 mg/m2/day.
Maltese: Minn dawn il-11il pazjent, 4 pazjenti eskalaw għal 800 mg kuljum, 2 minnhom kisbu mill-ġdid rispons riċitoġenetiku (1 pazjali u 1 komplet, tal-aħħar kiseb ukoll rispons molekulari), waqt li mis-7 pazjenti li ma eskalawx id-doża, wieħed biss kiseb mill-ġdid rispons ċitoġenetiku komplet.
English: Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/blast crisis at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p<0.001 overall, p=0.25 between CCyR and PCyR).
Maltese: Filwaqt li madwar 96 % (93 %) tal-pazjenti b'CCyR (PCyR) wara 12-il xahar kienu ħielsa minn avvanz għal fażi aċċellerata/blast crisis wara 84 xahar, 81 % tal-pazjenti biss mingħajr MCyR wara 12-il xahar kienu ħielsa minn avvanz għal CML avvanzata wara 84 xahar (p<0.
English: Imatinib Accord 100 mg film-coated tablets are brownish orange, round biconvex, film-coated tablets, debossed on one side with ‘IM' and ‘T1' on either side of breakline and plain on the other side.
Maltese: Imatinib Accord 100 mg pilloli miksija b'rita huma pilloli oranġjo fil-kannella, tondi, bikonvessi, miksija b'rita, imnaqqxa b'‘IM' fuq naħa waħda u b'‘T1' fuq kull naħa tas-sinjal minn fejn il-pillola tinqasam u lixxi fuq in-naħa l-oħra.
English: The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the Imatinib arm compared to the IFN arm (92.5% versus 85.1%, p<0.001).
Maltese: Ir-rata stmata ta' pazjenti mingħajr avvanz lejn fażi aċċellerata jew blast crisis wara 84 xahar kienet b'mod sinifikanti ogħla fil-fergħa b'Imatinib meta mqabbel mal-fergħa b'IFN (92.5 % kontra 85.1 %, p<0.001).
English: The recommended dosage of Imatib Accord is 400 mg/day for adult patients in chronic phase CML.
Maltese: Id-dożaġġ rakkomandat ta' Imatinib Accord huwa ta' 400 mg/jum għal pazjenti adulti li jkollhom CML fil-fażi kronika.
English: In this study, dose escalations were allowed from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily.
Maltese: F'dan l-istudju, l-eskalazzjonijiet tad-doża kienu permessi minn 400 mg kuljum għal 600 mg kuljum, imbagħad minn 600 mg kuljum għal 800 mg kuljum.
English: Carriers of HBV who require treatment with Imatinib Accord should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy (see section 4.8).
Maltese: Portatuti tal-HBV li jeħtieġu l-kura b'Imatinib Accord għandhom jiġu mmonitorjati mill-qrib għal sinjali u għal sintomi tal-infezzjoni attiva tal-HBV waqt ilkura u għal diversi xhur wara li tintemm il-kura (ara sezzjoni 4.8).
English: An observational registry (study L2401) was conducted to collect long-term safety and efficacy data in patients suffering from myeloproliferative neoplasms with PDGFR- β rearrangement and who were treated with imatinib.
Maltese: Inħoloq reġistru ta' osservazzjoni (studju L2401) sabiex tinġabar data dwar is-sigurtà u l-effikaċja fuq medda ta' żmien fost pazjenti li jbatu minn neoplażmi majeloproliferattivi b'arranġament PGDFR- β u li kienu ttrattati bi imatinib.
English: In a controlled study (ADE10) of imatinib versus chemotherapy induction in 55newly diagnosed patients aged 55 years and over, imatinib used as single agent induced a significantly higher rate of complete haematological response than chemotherapy (96.3% vs. 50%; p=0.0001).
Maltese: Imatinib użat waħdu wassal għal rispons ematoloġiku komplet b'rata ogħla minn kimoterapija (96.3% vs 50%; p=0.001).
English: 4 tablets of 100 mg or 1 tablet of 400 mg in the morning and 4 tablets of 100 mg or 1 tablet of 400 mg in the evening.
Maltese: Id-doża tal-bidu hija ta' 400 mg li għandha tittieħed bħala 4 pilloli ta' 100 mg jew pillola waħda ta 400 mg darba kuljum.
English: Your doctor will discuss with you the possible risks of taking Imatinib Accord during pregnancy.
Maltese: It-tabib tiegħek ser jiddiskuti r-riskji possibbli bl-użu ta' Imatinib Accord waqt it-tqala.
English: The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25-1,000 mg imatinib after oral administration.
Maltese: L-AUC medja tiżdied b'mod linjari ma' żieda fid-doża, u ż-żieda fl-AUC medja hija wkoll proporzjonali għad-doża f' dożi ta' bejn 25-1,000 mg ta' imatinib mill-ħalq.
English: Considering the limited safety database, the adverse events thus far reported in children and adolescents are consistent with the known safety profile in adult patients with Ph+ ALL.
Maltese: Meta wieħed iqis id-databażi limitata dwar is-sigurtà, l-episodji avversi rrappurtati sa issa fit-tfal u fladolexxenti huma konsistenti mal-profil magħruf tas-sigurtà f'pazjenti adulti b'Ph+ ALL.
English: Each film-coated tablet contains 400 mg of imatinib (as mesilate).
Maltese: Kull pillola miksija b'rita fiha 400 mg ta' imatinib (bħala mesilate).
English: In GIST patients (study B2222), 6.8% of grade 3 or 4 ALT (alanine aminotransferase) elevations and 4.8% of grade 3 or 4 AST (aspartate aminotransferase) elevations were observed.
Maltese: Il-kura kellha titwaqqaf għal kollox, minħabba abnormalitajiet fit-testijiet tal-laboratorju fuq il-funzjoni tal-fwied, f'inqas minn 1% tal-pazjenti b'CML.F'pazjenti b'GIST (studju B2222), żidiet ta' 6.8% tal-grad 3 jew 4 ALT (alanine aminotransferase) u żidiet ta' 4.8% ta' grad 3 jew 4 AST (aspartate aminotransferase) kienu evidenti.
English: Overall, in patients receiving first-line Imatinib, the average daily dose delivered was 406 ± 76 mg.
Maltese: B'mod ġenerali, f'pazjenti li kienu qed jirċievu Imatinib tal-ewwel linja, id-doża medja ta' kuljum li ngħatat kienet ta' 406 ± 76 mg.
English: When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females.
Maltese: Meta firien tassess feminili ngħataw il-kura minn 14-il jum qabel ma tgħammru sas-6 jum tat-tqala, ma kien hemm lebda effett fuq it-tgħammir jew fuq in-numru ta' firien li ħarġu tqal.
English: (DRESS)* , pseudoporphyria*
Maltese: Xokk anafilattiku*
English: DEX 40 mg/day on days 1-4 and 11-14, alternated with MTX 1 g/ m2 i.v.
Maltese: DEX 40 mg/jum f'jiem 1-4 u 11-14, alternati b'MTX 1 g/m2 i.v. (24 h), jum 1, Ara-C 1 g/m2 i.v. (2 h, q 12 h), jiem 2-3 (total ta' 8 korsijiet)
English: Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib (see section 4.5).
Maltese: Każijiet kliniċi ta' ipertajrojdiżmu kienu rapurtati f'pazjenti li tneħħitilhom it-tajrojd li jkunu qed jirċievu terapija b'levothyroxine waqt il-kura b'imatinib (ara sezzjoni 4.5).
English: Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
Maltese: Il-metaboliżmu ta' imatinib issir l-aktar permezz tal-fwied, u 13% biss tal-eskrezzjoni hija minn ġolkliewi.
English: No significant age-related pharmacokinetic differences have been observed in adult patients in clinical trials which included over 20% of patients age 65 and older.
Maltese: Fi provi kliniċi li fihom aktar minn 20% tal-pazjenti kellhom 65 sena jew aktar, ma deherx li kien hemm xi differenzi farmakokinetiċi sinifikanti li għandhom x'jaqsmu mal-eta, f'pazjenti adulti.
English: The rate ofresponse was also higher in the patients treated at 600 mg (33%) as compared to the patients treated at 400 mg (16%, p=0.0220).
Maltese: Ir-rata tar-rispons kienet ukoll ogħla fil-pazjenti li ħadu doża ta' 600 mg (33%) meta mqabbla mal-pazjenti li kienu ħadu doża ta' 400 mg (16%, p=0.0220).
English: Each 400 mg film-coated tablet of Imatinib Accord contains 400 mg imatinib (as mesilate).
Maltese: Kull pillola miksija b'rita ta' 400 mg ta' Imatinib Accord fiha 100 mg imatinib (bħal mesilate).
English: (3 h, q 12 h), days 1-3; Vincristine 2 mg i.v., days 4, 11;
Maltese: Reġimen iper-CVAD: CP 300 mg/m2 i.v. (3 h, q 12 h), jiem 1-3; Vincristine 2 mg i.v., jiem 4, 11;
English: Cerebral oedema*
Maltese: Emorraġija fil-vitriju*
English: The recommended dosage of Imatinib Accord is 600 mg/day for adult patients in accelerated phase.
Maltese: Id-dożaġġ rakkomandat ta' Imatinib Accord huwa ta' 600 mg/jum għal pazjenti adulti fil-fażi aċċellerata.
English: Hypokalaemia, increased appetite, hypophosphataemia, decreased appetite, dehydration, gout, hyperuricaemia, hypercalcaemia, hyperglycaemia, hyponatraemia
Maltese: Ipokalimija, żieda fl-aptit, ipofosfatemija, nuqqas ta' aptit, deidrazzjoni, gotta, iperuriċemija, iperkalċimija, ipergliċimija, iponatrimija
English: Severe elevation of transaminases (< 5%) or bilirubin (< 1%) was seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week).
Maltese: Żieda qawwija fil-livelli tat-transaminases (< 5%) jew tal-bilirubin (< 1%) kienet evidenti f'pazjenti b'CML u s-soltu kienet kontrollata bi tnaqqis fid-doża jew inkella billi kien imwaqqaf għal ftit żmien it-trattament (it-tul medjan ta' dawn l-episodji kien ta' bejn wieħed u ieħor, ġimgħa).
English: G-CSF (5 μg/kg, SC): days 4-13 or until ANC > 1500 post nadir
Maltese: ARA-C (3 g/m2/doża q 12 h x 4, IV): jiem 2 u 3 G-CSF (5 μg/kg, SC): jiem 4-13 jew sa ANC > 1500 postnadir
English: All patients received imatinib and consolidation chemotherapy (see Table 3) after induction and the levels of bcr-abl transcripts were identical in the two arms at 8 weeks.
Maltese: Il-pazjenti kollha rċevew imatinib u terapija konsolidata (ara Tabella 3) wara induzzjoni u l-livelli ta' bcr-abl transcripts kienu identiċi fiżżewġ friegħi mat-8 ġimgħa.
English: Maintenance (8-week cycles) Cycles 1cy
Maltese: Manutenzjoni (ċikli ta' 8-ġimgħat)
English: Dose adjustments for neutropenia and thrombocytopenia: HES/CEL (starting dose 100 mg)
Maltese: 4-il darba l-esponiment fit-tfal u fl-adolexxeneti (bażat fuq lAUC) b'340 mg/m2/jum.
English: Daunorubicin 60 mg/ m2 i.v.
Maltese: Vindesine 3 mg/m2 i.v., jum 1;
English: Dose adjustments do not seem to be necessary when imatinib is co-administrated with CYP2D6 substrates, however caution is advised for CYP2D6 substrates with a narrow therapeutic window such as metoprolol.
Maltese: Tibdil fid-doża ma jidhrux li huma neċessarji meta imatinib jingħata flimkien ma' sottostrati ta' CYP2D6, madankollu hija konsiljata lattenzjoni għal sottostrati ta' CYP2D6 b'medda terapewtika dejqa bħal metoprolol.
English: A total of 1,106 patients were randomised, 553 to each arm. Baseline characteristics were well balanced between the two arms.
Maltese: Ġew randomizzati total ta' 1,106 pazjenti, 553 għal kull fergħa.
English: bone pain10
Maltese: Ċiklu 5
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Maltese: Ir-rekwiżiti biex jiġu ppreżentati rapporti perjodiċi aġġornati dwar is-sigurta għal dan il-prodott mediċinali li huma mniżżla fil-lista tad-dati ta' referenza tal-Unjoni (lista EURD) prevista skont lArtikolu 107c(7) tad-Direttiva 2001/83/KE u kwlunkwe aġġornament sussegwenti ppubblikat fuq ilportal elettroniku Ewropew tal-mediċini.
English: There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken imatinib.
Maltese: Kien hemm rapporti li saru wara li lprodott tqiegħed fis-suq dwar abborti spontanji u anomaliji konġenitali fi trabi minn nisa li ħadu imatinib.
English: An increased rate of opportunistic infections was observed with chronic imatinib treatment.
Maltese: Kien hemm rata ogħla ta' infezzjonijiet opportunistiċi meta imatinib ingħata fittul.
English: This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to Imatinib.
Maltese: Meta l-livelli jinżlu, imatinib jista' imbagħad jitkompla b'doża ta' kuljum imnaqqsa.
English: The remaining circulating radioactivity consisted of a number of minor metabolites.
Maltese: Ir-radjuattivita l-oħra fiċ-ċirkolazzjoni kienet minħabba numru ta'metaboli minuri.
English: 16 December 2016 EMA/822770/2016 EMEA/H/C/004023
Maltese: EMA/822770/2016 EMEA/H/C/004023
English: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim) EMA/822770/2016
Maltese: (pegfilgrastim) EMA/822770/2016
English: On 16 November 2016, Gedeon Richter Plc officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Efgratin, for reducing neutropenia.
Maltese: Fis-16 ta' Novembru 2016, Gedeon Richter Plc għarrfet uffiċjalment lill-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) bl-intenzjoni li tirtira l-applikazzjoni tagħha għallawtorizzazzjoni għat-tqegħid fis-suq għal Efgratin, għat-tnaqqis tan-newtropenja.
English: What is Efgratin?
Maltese: X'inhu Efgratin?
English: Efgratin was developed as a ‘biosimilar' medicine.
Maltese: Efgratin ġie żviluppat bħala mediċina ‘bijosimili'.
English: The active substance in Efgratin, pegfilgrastim, consists of filgrastim that has been 'pegylated' (attached to a chemical called polyethylene glycol).
Maltese: Is-sustanza attiva f'Efgratin, il-pegfilgrastim, hija magħmula minn filgrastim li jkun ġie ‘pegilat' (imwaħħal ma' sustanza kimika msejħa polietilenglikol).
English: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)
Maltese: L-irtirar tal-applikazzjoni għall-awtorizzazzjoni għattqegħid fis-suq għal Efgratin (pegfilgrastim)
English: What was Efgratin expected to be used for?
Maltese: Għal xiex kien mistenni li jintuża Efgratin?
English: Efgratin is a medicine that contains the active substance pegfilgrastim, which stimulates the production of neutrophils (a type of white blood cell that fights infections).
Maltese: Efgratin huwa mediċina li fiha s-sustanza attiva pegfilgrastim, li tistimula l-produzzjoni ta' newtrofili (tip ta' ċelloli bojod tad-demm li jiġġieldu l-infezzjonijiet).
English: The company presented results of studies in healthy people designed to show that Efgratin is highly similar to its reference medicine Neulasta in terms of chemical structure, purity, the way it works and how the body handles the medicine.
Maltese: Il-kumpanija ppreżentat riżultati ta' studji ta' persuni b'saħħithom imfassla sabiex juru li Efgratin huma simili ħafna għall-mediċina ta' referenza tiegħu Neulasta f'termini ta' struttura kimika, purità, il-mod kif jaħdem u l-mod kif il-ġisem juża l-mediċina.
English: Efgratin was to be used to reduce the duration of neutropenia and the occurrence of febrile neutropenia (neutropenia with fever).
Maltese: Efgratin kellu jintuża sabiex inaqqas id-durata ta' newtropenja u l-okkorrenza ta' newtropenja febbrili (newtropenja bid-deni).
English: The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for Efgratin.
Maltese: Il-kumpanija infurmat lis-CHMP li ma hemm ebda prova klinika għaddejja jew programm ta' użu b'kumpassjoni għal Efgratin.
English: Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Efgratin could not have been approved for reducing neutropenia.
Maltese: Fuq il-bażi tar-rieżami tad-data u t-tweġibiet tal-kumpanija għal-lista ta' mistoqsijiet tas-CHMP, fiżżmien tal-irtirar, is-CHMP kellu xi tħassib u kien tal-idea provviżorja li Efgratin ma setax jiġi approvat għat-tnaqqis ta' newtropenja.
English: The CHMP was concerned that study results had not shown that Efgratin was handled by the body in the same way as the reference medicine Neulasta.
Maltese: Dan ifisser li Efgratin kien intiż li jkun simili ħafna għal mediċina bijoloġika (il-‘mediċina ta' referenza') li diġà tinsab awtorizzata fl-Unjoni Ewropea msejħa Neulasta.
English: The full EPAR for Abraxane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Abraxane is given into a vein over a period of 30 minutes.
Maltese: Abraxane jingħata ġol-vina fuq perjodu ta' 30 minuta.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku paklitaksel
English: The most common important side effects with Abraxane (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, a type of white blood cells), gastrointestinal disorders (disorders of the digestive system), peripheral neuropathy (nerve damage including damage to the nerves in the hand and feet), arthralgia (joint pain) and myalgia (muscle pain).
Maltese: L-effetti sekondarji importanti l-aktar komuni b'Abraxane (li dehru f'aktar minn pazjent 1 minn kull 10) huma newtropenija (livelli baxxi ta' newtrofili, tip ta' ċelloli tad-demm bojod), disturbi gastrointestinali (disturbi tas-sistema diġestiva), newropatija periferika (ħsara fin-nervituri inkluża ħsara lin-nervituri tal-idejn u tas-saqajn), artralġija (uġigħ fil-ġogi) u mijalġija (uġigħ fil-muskoli).
English: This document is a summary of the European Public Assessment Report (EPAR) for Abraxane.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Abraxane.
English: The recommended dose is 125 mg per square metre of body surface area once a day on days 1, 8 and 15 of each cycle.
Maltese: Id-doża rakkomandata hija ta' 125 mg għal kull metru kwadru tal-erja tas-superfiċje tal-ġisem darba kuljum fil-jiem 1, 8 u 15 ta' kull ċiklu.
English: It contains the active substance paclitaxel attached to a human protein called albumin.
Maltese: Fih is-sustanza attiva lpaklitaksel li teħel mal-proteina umana msejħa albumina.
English: For non-small cell lung cancer, the Abraxane-carboplatin combination was compared with a combination of a conventional paclitaxel-containing medicine and carboplatin in 1,052 patients.
Maltese: Għall-kanċer tal-pulmum ta' ċellola mhux żgħira, il-kombinazzjoni Abraxane-carboplatin tqabblet ma' kombinazzjoni ta' mediċina konvenzjonali li fiha l-paklitaksel u carboplatin f'1,052 pazjent.
English: Abraxane paclitaxel
Maltese: Aktar tagħrif dwar Abraxane
English: The European Commission granted a marketing authorisation valid throughout the European Union for Abraxane on 11 January 2008.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Abraxane fil-11 ta' Jannar 2008.
English: Overall, in the main study, 31% of the women receiving Abraxane responded to treatment (72 out of 229), compared with 16% of the women receiving conventional paclitaxel-containing medicines (37 out of 225).
Maltese: B'mod ġenerali, fl-istudju ewlieni, 31% tan-nisa li ngħataw Abraxane rrispondew għall-kura (72 minn 229), meta mqabbla ma' 16% tan-nisa li ngħataw mediċini konvenzjonali li fihom ilpaklitaksel (37 minn 225).)
English: In non-small cell lung cancer, 33% of patients receiving Abraxane and carboplatin responded to treatment compared with 25% of those receiving conventional paclitaxel and carboplatin.
Maltese: Fil-kanċer tal-pulmun ta' ċellola mhux żgħira, 33% tal-pazjenti li ngħataw Abraxane u carbopatin irrispondew għall-kura meta mqabbla ma' 25% ta' dawk li ngħataw il-paklitaksel konvenzjonali u carboplatin.
English: In Abraxane, unlike conventional paclitaxel-containing medicines, the paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles'.
Maltese: F'Abraxane, b'differenza għal mediċini konvenzjonali li fihom il-paklitaksel, il-paklitaksel teħel mal-proteina umana msejħa albumina f'partikuli żgħar imsejħa ‘nanopartikuli'.
English: The recommended dose of Abraxane is 100 mg per square metre of body surface area.
Maltese: Id-doża rakkomandata ta' Abraxane hija 100 mg għal kull metru kwadru tal-erja tas-superfiċje tal-ġisem.
English: For additional information, see the summary of product characteristics (also part of the EPAR).
Maltese: Għal aktar informazzjoni, ara s-sommarju ta' karatteristiċi tal-prodott (parti wkoll mill-EPAR).
English: Patients survived for around 8.5 months on treatment with the combination of Abraxane and gemcitabine, compared with 6.7 months on gemcitabine alone.
Maltese: Ilpazjenti għexu għal madwar 8.5 xhur fuq il-kura bil-kombinazzjoni ta' Abraxane u gemcitabine, meta mqabbla ma' 6.7 xhur fuq gemcitabine waħdu.
English: A response was defined as the patient's main tumours disappearing or shrinking in size by at least 30%.
Maltese: Rispons kien definit bħala meta t-tumuri ewlenin tal-pazjent jisparixxu jew jonqsu fid-daqs b'tal-inqas 30%.
English: In non-small cell lung cancer, treatment is carried out in 3-week cycles with Abraxane given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Abraxane.
Maltese: Fil-kanċer tal-pulmun ta' ċellola mhux żgħira, il-kura tingħata f'ċikli ta' 3 ġimgħat b'Abraxane li jingħata fil-jiem 1, 8 u 15 ta' kull ċiklu u carboplatin jingħata fl-1 jum eżatt wara Abraxane.
English: Why has Abraxane been approved?
Maltese: Għaliex ġie approvat Abraxane?
English: Abraxane given on its own was compared with a conventional paclitaxel-containing medicine given together with other medicines to reduce side effects.
Maltese: Abraxane meta ngħata waħdu tqabbel ma' mediċina konvenzjonali li fiha l-paklitaksel li ngħatat flimkien ma' mediċini oħra għat-tnaqqis tal-effetti sekondarji.
English: • metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine.
Maltese: • adenokarċinoma metastatika tal-frixa, bħala l-ewwel kura flimkien ma' mediċina oħra kontra lkanċer, gemcitabine.
English: The medicine can only be obtained with a prescription.
Maltese: Ma għandux jiġi sostitwit b'mediċini oħra li fihom il-paklitaksel.
English: Abraxane is a powder that is made up into a suspension for infusion (drip) into a vein.
Maltese: Abraxane huwa trab magħmul f'sospensjoni għall-infużjoni (dripp) fil-vina.
English: What is the risk associated with Abraxane?
Maltese: X'inhu r-riskju assoċjat ma' Abraxane?
English: What is Abraxane?
Maltese: X'inhu Abraxane?
English: The active substance in Abraxane, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes'.
Maltese: Is-sustanza attiva f'Abraxane, il-paklitaksel, tappartjeni għall-grupp ta' mediċini kontra l-kanċer magħrufa bħala ‘tassani'.
English: In metastatic breast cancer, Abraxane was more effective than conventional paclitaxel-containing medicines.
Maltese: Fil-kanċer metastatiku tas-sider, Abraxane kien iktar effikaċi mill-mediċini konvenzjonali li fihom ilpaklitaksel.
English: Immediately after giving Abraxane gemcitabine should be given at a dose of 1000 mg per square metre of body surface area.
Maltese: Eżatt wara li jingħata Abraxane għandu jingħata gemcitabine f'doża ta' 1000 mg għal kull metru kwadru tal-erja tas-superfiċje tal-ġisem.